New Jersey 2022-2023 Regular Session

New Jersey Assembly Bill A1478

Introduced
1/11/22  

Caption

Provides for funds received from opioid litigation or settlements to be dedicated for use in financing substance use disorder prevention and treatment programs and services in New Jersey.

Impact

By mandating that funds received through settlement agreements are to be used solely for financing substance use disorder services, A1478 aims to eliminate potential misallocation of these funds, an issue that has plagued similar past settlements related to tobacco. The bill highlights a commitment to direct at least a portion of the financial resources from opioid-related legal actions towards effective treatment mechanisms. This is particularly crucial as the pandemic has exacerbated the challenges faced by individuals struggling with addiction, compounding the urgent necessity for consistent and expanded treatment options.

Summary

Assembly Bill A1478 seeks to address the ongoing opioid crisis in New Jersey by establishing the 'Opioid Settlement Treatment Support Fund.' This non-lapsing fund is designed to specifically allocate resources obtained from legal settlements with opioid manufacturers and distributors, ensuring these funds are dedicated exclusively to enhance and modernize substance use disorder prevention and treatment programs and services within the state. The legislative intent behind this bill reflects the pressing need for targeted funding to combat the devastating effects of the opioid epidemic, which has claimed numerous lives and strained social services across the state.

Contention

The legislation anticipates significant financial inflows due to ongoing litigation against opioid companies, with projections suggesting that New Jersey could see hundreds of millions in settlements. However, critics remain wary of the management and distribution of these funds, fearing that without stringent oversight, other legislative priorities may divert these critical resources away from their intended purpose. Additionally, some stakeholders argue for a more comprehensive approach to address systemic issues related to addiction, which this bill may not fully encapsulate.

Companion Bills

No companion bills found.

Previously Filed As

NJ AB1081

Modifying administrative rules relating to regulation of opioid treatment programs and requiring adjustments to the rates for substance use disorder treatment services with medications for opioid use disorder. (FE)

NJ SB1047

Modifying administrative rules relating to regulation of opioid treatment programs and requiring adjustments to the rates for substance use disorder treatment services with medications for opioid use disorder. (FE)

NJ A2268

Requires certain providers of substance or alcohol use disorder treatment, services, or supports to be assessed for conflicts of interest prior to receiving State funds, licensure, or certification.

NJ A626

Increases access to substance use disorder treatment; Requires Medicaid coverage for substance use disorder services provided by community-based organizations.

NJ A2599

Establishes "Substance Use Disorder and Addiction Treatment Best Practices Task Force."

NJ S3990

Requires certain providers of substance or alcohol use disorder treatment, services, or supports to be assessed for conflicts of interest prior to receiving State funds, licensure, or certification.

NJ S2492

Increases access to substance use disorder treatment; Requires Medicaid coverage for substance use disorder services provided by community-based organizations.

NJ A11184

Reforms the opioid settlement board to provide services and supports to grieving families and include board members who lost a child, sibling, parent or close family member to substance use disorder.

NJ HB718

Opioid use disorder; require substance use disorder facilities to provide pregnant women with onsite access to certain treatments.

NJ A782

Revises licensure requirements for residential substance use disorders treatment facilities or programs.

Similar Bills

No similar bills found.